Search results
...Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual...
Benzinga· 3 hours agoThe KOL event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of ...
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 hours agoAnd third, it may have broad utility across many different autoimmune and inflammatory diseases, and this trial may provide proof of concept for the treatment of other immune ...
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 5 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 7 hours agoThe complexity and uncertainty of clinical trial outcomes, particularly as Corvus Pharmaceuticals Inc (NASDAQ:CRVS) ventures into new treatment areas like atopic& ...
Review Addresses Skin Manifestations of Cystic Fibrosis
Medscape· 1 day agoA review covers the various skin manifestations seen in patients with CF, which include those...
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks via Yahoo Finance· 7 days agoOpzelura cream 1.5% is approved for the topical treatment of non-segmental vitiligo in adult and...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After...
Fairfield-Suisun Daily Republic· 5 days agoNektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President ...
Gene expression analyses identify potential drivers of chronic allergic inflammation
Medical Xpress· 7 days agoCurrently, most therapies for allergic diseases require lifelong treatment. Allergic reactions, characterized by ongoing (type 2) inflammation in response to chronic antigen ...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 5 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 4 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
